



# NEVADA STATE BOARD OF PHARMACY

431 W. Plumb Lane • Reno, NV 89509

(775) 850-1440 • 1-800-364-2081 • FAX (775) 850-1444

• Web Page: [bop.nv.gov](http://bop.nv.gov)

## **NVBOP Collaborative Practice Agreement Information**

**December 2017**

### **Definitions**

Collaborative drug therapy management – initiating, monitoring, modifying or discontinuing a patient’s drug therapy by one or more pharmacists under the supervision of one or more practitioners in accordance with a collaborative practice agreement.

Collaborative practice agreement – an agreement that meets the requirements of section 5 of SB260 between one or more pharmacists and one or more practitioners which authorizes a pharmacist to engage in the collaborative practice of pharmacy or collaborative drug therapy management.

Collaborative practice of pharmacy – the performance of tests to address chronic diseases and public health issues, including, without limitation, outbreaks and occurrences of specific diseases and disorders, by one or more pharmacists in collaboration with one or more practitioners in accordance with a collaborative practice agreement.

### **Criteria for collaborative practice agreements**

- May be performed at any location within the state.
- Must be signed by each practitioner and pharmacist who enter into the collaborative practice agreement.
- Must be submitted to the NVBOP in written and electronic form.
- A practitioner may not enter into a collaborative practice agreement with a pharmacist for the management of controlled substances.
- A pharmacy must not require a registered pharmacist, as a condition of employment, to enter into a collaborative practice agreement.
- Must expire not later than 1 year after the date on which the agreement becomes effective. The parties to a collaborative practice agreement may renew the agreement after reviewing the agreement and making any necessary revisions.
- May authorize a pharmacist to order and use the findings of laboratory tests and examinations if approved by the Board.
- Must state the conditions under which a prescription of a practitioner relating to drug therapy of a patient may be changed by the pharmacist without a subsequent prescription from the practitioner if applicable.

### **General responsibilities of the practitioner**

As a practitioner entering into a collaborative practice agreement I agree to the following:

- Be licensed in good standing to practice his/her profession in this State.
- Agree to maintain an ongoing relationship with a patient who is referred by the practitioner to a pharmacist pursuant to a collaborative practice agreement for collaborative drug therapy management.
- Agree to obtain the informed, written consent from a patient who is referred by the practitioner to a pharmacist pursuant to a collaborative practice agreement for collaborative drug therapy management.
- Except as otherwise provided in this statement, actively practice his/her profession within 100 miles of the primary location where the collaborating pharmacist practices in this State. A practitioner and pharmacist may submit a written request to the Board for an exemption from the requirements of this statement. The Board may grant such a request upon showing of good cause.

### **General responsibilities of the pharmacist**

As a pharmacist entering into a collaborative practice agreement I agree to the following:

- Document any treatment or care provided to a patient pursuant to a collaborative practice agreement after providing such treatment or care in the medical record of the patient, on the chart of the patient or in a separate log book.
- Document in the medical record of the patient, on the chart of the patient or in a separate log book any decision or action concerning the management of drug therapy pursuant to a collaborative practice agreement after making such a decision or taking such an action.
- Maintain all records concerning the care or treatment provided to a patient pursuant to a collaborative practice agreement in written or electronic form for at least 7 years.
- Comply with all HIPAA regulations as well as all other federal and state laws and regulations concerning the privacy of information regarding health care.
- Provide the patient with written notification of any test administered by the pharmacist and the results of such test, the name of any drug or prescription filled and dispensed by the pharmacist to the patient, and the contact information of the pharmacist **(required addendum to CPA)**
- A pharmacist who modifies a drug therapy of a patient receiving care in a setting that is affiliated with a medical facility, shall, within 72 hours after initiating or modifying the drug therapy, provide written notice of the initiation or modification of the drug therapy to the collaborating practitioner or enter the appropriate information concerning the drug therapy in an electronic patient record system shared by the pharmacist and collaborating practitioner.

### **Informed written consent (required addendum to CPA)**

A pharmacist shall obtain the informed, written consent of a patient before engaging in the collaborative practice of pharmacy on behalf of the patient. Such written consent must include, without limitation, a statement that the pharmacist may initiate, modify or discontinue the medication of the patient pursuant to a collaborative practice agreement, is not a physician, osteopathic physician, advanced practice registered nurse or physician assistant and may not diagnose.

### **Required elements of Collaborative Practice Agreement**

**Prior to submitting a CPA for approval please review all of the required elements below to confirm that they are included in the agreement.**

- A description of the types of decisions concerning the management of drug therapy that the pharmacist is authorized to make, which may include a specific description of the diseases and drugs for which the pharmacist is authorized to manage drug therapy. **(required addendum to CPA). Addendum must include detailed information on drug therapy protocols.**
- A detailed explanation of the procedures that the pharmacist must follow when engaging in the collaborative practice of pharmacy, including, without limitation, the manner in which the pharmacist must document decisions concerning treatment and care in accordance with the general pharmacist responsibilities listed above, report such decisions to the practitioner and receive feedback from the practitioner. **(required addendum to CPA)**
- The procedure by which the pharmacist will notify the practitioner of an adverse event concerning the health of the patient.
- The procedure by which the practitioner will provide the pharmacist with a diagnosis of the patient and any other medical information necessary to carry out the patient's drug therapy management.
- A description of the means by which the practitioner will monitor clinical outcomes of a patient and intercede when necessary to protect the health of the patient or accomplish the goals of the treatment prescribed for the patient.
- Authorization for the practitioner to override the agreement if necessary to protect the health of the patient or accomplish the goals of the treatment prescribed for the patient.
- Authorization for either party to terminate the agreement by written notice to the other party, which must include, without limitation, written notice to the patient that informs the patient of the procedures by which he or she may continue drug therapy.
- The effective date of the agreement.
- The date by which a review must be conducted for renewal of the collaborative practice agreement, which must be not later than the expiration date of the agreement.
- The address of the location where the records will be maintained.
- The process by which the pharmacist will obtain the informed, written consent of the patient.
- Qualifications and training required for pharmacists entering into CPA is recommended.
- Annual competency documentation for pharmacists entering into CPA is recommended.